Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential
Analyst recommends Novartis as a Buy for long-term investors, BioAge a Hold, following strategic partnership for age-related ...
PTC Therapeutics: Navigating Revenue Challenges and Uncertain Outlook Amidst DMD Franchise Erosion
Leerink Partners analyst Joseph Schwartz has maintained their neutral stance on PTCT stock, giving a Hold rating yesterday.Stay Ahead of the ...
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...
Cautious Outlook on PTC Therapeutics Amid Regulatory and Financial Challenges
PTC Therapeutics (PTCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Lebowitz ...
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common ...
news.stocktradersdaily8h
When (PTCT) Moves Investors should Listen
Check the time stamp on this data. Updated AI-Generated Signals for Ptc Therapeutics Inc. (PTCT) available here: PTCT. Type a ...
Gabrielle White appointed president of Irish Exporters Association
Gabrielle White has been appointed as president of the Irish Exporters Association, the organisation said on Thursday. She ...
Morningstar4d
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew ...
Finanznachrichten3d
PTC Therapeutics, Inc.: PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing ...
Investing6d
Ptc Therapeutics' chief accounting officer sells $132,492 in stock
Christine Marie Utter, Senior Vice President and Chief Accounting Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), recently sold shares of the company's common stock totaling $132,492. The ...